Andrew C Scott

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3875546/publications.pdf Version: 2024-02-01



ANDREW C SCOTT

#	Article	IF	CITATIONS
1	TOX is a critical regulator of tumour-specific T cell differentiation. Nature, 2019, 571, 270-274.	27.8	697
2	Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature, 2017, 545, 452-456.	27.8	643
3	Targeting the Intracellular WT1 Oncogene Product with a Therapeutic Human Antibody. Science Translational Medicine, 2013, 5, 176ra33.	12.4	147
4	Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. Nature Biotechnology, 2015, 33, 1079-1086.	17.5	134
5	A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens. Journal of Clinical Investigation, 2017, 127, 2705-2718.	8.2	63
6	A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias. Blood, 2014, 123, 3296-3304.	1.4	52
7	Mechanisms of resistance to high and low linear energy transfer radiation in myeloid leukemia cells. Blood, 2012, 120, 2087-2097.	1.4	27
8	Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody. Oncolmmunology, 2019, 8, e1570778.	4.6	19
9	Ectopic activation of the miR-200c–EpCAM axis enhances antitumor T cell responses in models of adoptive cell therapy. Science Translational Medicine, 2021, 13, eabg4328.	12.4	8
10	A Therapeutic TCR Mimic Monoclonal Antibody for Intracellular PRAME Protein in Leukemias. Blood, 2015, 126, 2527-2527.	1.4	5
11	WilmsÂTumor 1 Protein Is Highly Expressed on Malignant Plasma Cells and Provides a Novel Target for Immunotherapeutic Approaches, Blood, 2015, 126, 98-98	1.4	2